The Rockefeller University

Summary

The Rockefeller University is a medical facility located in New York, New York. This center is recognized for care of Obesity, Psoriasis, HIV/AIDS, Healthy Subjects, AIDS and other specialties. The Rockefeller University is involved with conducting 89 clinical trials across 83 conditions. There are 3 research doctors associated with this hospital, such as Marina Caskey, MD, Amihai Rottenstreich, MD, and Martina Turroja, MD.

Top PIs

Clinical Trials running at The Rockefeller University

Hepatitis B

Entecavir for Hepatitis B

Obesity

Iron and Trace Metal Metabolism Disorders

Cold Exposure

Metabolic Diseases

Pre-eclampsia

Prophylaxis of Preeclampsia

Hepatitis B Vaccine

for Hepatitis B

Antibodies are the primary mediators of the protection against infection provided by vaccination. Antibodies become most powerful after the B cells that produce them undergo an evolutionary process called affinity maturation, in which antibodies increase their ability to bind to their targets, and thus neutralize pathogens. Affinity maturation occurs in structures within secondary lymphoid organs (for example lymph nodes or tonsils) known as germinal centers. Germinal centers are well known to be triggered by the first dose of vaccines, generating affinity matured plasma cells (B cells that secrete antibody into serum) and memory B cells, which can be converted into plasma cells by booster doses of vaccine. However, it is not fully understood the extent to which memory B cells can return to germinal centers again upon vaccine boosting. Such return would be very important to allow B cells, for example, to adapt to emerging variants of viruses such as influenza or SARS-CoV-2. This study will involve acquiring samples of B cells from germinal centers that form in response to vaccination with the highly effective hepatitis B vaccine. These cells will be analyzed to determine what fraction of them are memory B cells that returned to germinal centers upon boosting, information that is key to knowledge of how vaccine boosters work. Understanding the "rules" that govern how and when memory B cells choose to return to germinal centers in an effective vaccine such hepatitis B could help efforts to develop effective vaccination against more challenging, rapidly mutating viruses, such as influenza, HIV, and hepatitis C.

Recruiting

3 awards

Phase 4

3 criteria

HepB mAb19

for Chronic Hepatitis B

This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B (CHB) on nucleos(t)ide analog therapy (NRTI).

Recruiting

0 awards

Phase 1

1 criteria